IL124954A - Inhibitors of interleukin-1betaconverting enzyme and pharmaceutical compositions containing the same - Google Patents

Inhibitors of interleukin-1betaconverting enzyme and pharmaceutical compositions containing the same

Info

Publication number
IL124954A
IL124954A IL12495496A IL12495496A IL124954A IL 124954 A IL124954 A IL 124954A IL 12495496 A IL12495496 A IL 12495496A IL 12495496 A IL12495496 A IL 12495496A IL 124954 A IL124954 A IL 124954A
Authority
IL
Israel
Prior art keywords
interleukin
pharmaceutical compositions
compounds
inhibitors
diseases
Prior art date
Application number
IL12495496A
Other languages
English (en)
Other versions
IL124954A0 (en
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IL124954A0 publication Critical patent/IL124954A0/xx
Publication of IL124954A publication Critical patent/IL124954A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
IL12495496A 1995-12-20 1996-12-20 Inhibitors of interleukin-1betaconverting enzyme and pharmaceutical compositions containing the same IL124954A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/575,648 US5843904A (en) 1995-12-20 1995-12-20 Inhibitors of interleukin-1βconverting enzyme
PCT/US1996/020370 WO1997022618A1 (fr) 1995-12-20 1996-12-20 INHIBITEURS DE L'ENZYME CONVERTISSANT L'INTERLEUKINE-1$g(b)

Publications (2)

Publication Number Publication Date
IL124954A0 IL124954A0 (en) 1999-01-26
IL124954A true IL124954A (en) 2005-11-20

Family

ID=24301162

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12495496A IL124954A (en) 1995-12-20 1996-12-20 Inhibitors of interleukin-1betaconverting enzyme and pharmaceutical compositions containing the same

Country Status (21)

Country Link
US (2) US5843904A (fr)
EP (1) EP0876395B1 (fr)
JP (3) JP4009320B2 (fr)
KR (1) KR20000064454A (fr)
CN (2) CN1127511C (fr)
AT (1) ATE310011T1 (fr)
AU (1) AU722936B2 (fr)
BR (1) BR9612191A (fr)
CA (1) CA2240489A1 (fr)
CZ (1) CZ292633B6 (fr)
DE (1) DE69635458T2 (fr)
HK (1) HK1016611A1 (fr)
HU (1) HUP9902254A3 (fr)
IL (1) IL124954A (fr)
NO (1) NO982774L (fr)
NZ (1) NZ326555A (fr)
PL (1) PL188813B1 (fr)
RU (1) RU2213096C2 (fr)
TR (1) TR199801168T2 (fr)
WO (1) WO1997022618A1 (fr)
ZA (1) ZA9610797B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
AU739321B2 (en) * 1996-09-12 2001-10-11 Idun Pharmaceuticals, Incorporated C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6054446A (en) * 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
CN1297354A (zh) * 1998-03-16 2001-05-30 西托维亚公司 二肽卡斯帕酶抑制剂及其用途
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
WO2000051998A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
TW200404789A (en) * 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
KR20010110667A (ko) 1999-03-16 2001-12-13 추후보정 치환 2-아미노벤즈아미드 카스파제 저해제 및 그것의 용도
WO2000061542A1 (fr) 1999-04-09 2000-10-19 Cytovia, Inc. Inhibiteurs de la caspase et leur utilisation
MXPA02001349A (es) * 1999-08-09 2002-07-22 Tripep Ab Inhibidores de la polimerizacion de proteinas y metodos de uso.
EA200200301A1 (ru) 1999-08-27 2002-08-29 Сайтовиэ, Инк. ЗАМЕЩЕННЫЕ α-ГИДРОКСИКИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ КЛЕТОЧНОЙ ГИБЕЛИ НА КЛЕТОЧНОМ ИЛИ ТКАНЕВОМ УРОВНЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ОБЛЕГЧЕНИЯ СОСТОЯНИЯ ПРИ ГИБЕЛИ КЛЕТОК У ЖИВОТНОГО, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ БОЛЕЗНЕЙ
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
WO2001087328A2 (fr) * 2000-05-12 2001-11-22 Immunex Corporation Inhibiteurs d"interleukine 1 dans le traitement de maladies
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
CA2421172A1 (fr) 2000-09-08 2002-03-14 Merck Frosst Canada & Co. Dipeptides a gamma cetoacide servant d'inhibiteurs de caspase-3
PE20020500A1 (es) * 2000-09-13 2002-06-25 Vertex Pharma Derivados de piperidina, tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
WO2002060859A2 (fr) 2000-12-20 2002-08-08 Bristol-Myers Squibb Company Derives cycliques utilises comme modulateurs de l'activite des recepteurs de chimiokines
JP2005506949A (ja) * 2000-12-20 2005-03-10 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー ケモカイン受容体の調節剤としてのジアミン
US20050074434A1 (en) * 2001-02-23 2005-04-07 Tomoaki Hoshino Remedies for metabolic bone diseases
CN1494425B (zh) 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
WO2002069965A1 (fr) 2001-03-05 2002-09-12 Transtech Pharma, Inc. Agents thérapeutiques à base de dérivés benzimidazole
CA2456762A1 (fr) * 2001-08-07 2003-02-20 Immunex Corporation Recepteurs de l'interleukine-1 dans le traitement de maladies
US6593455B2 (en) * 2001-08-24 2003-07-15 Tripep Ab Tripeptide amides that block viral infectivity and methods of use thereof
EP1436317A1 (fr) * 2001-09-19 2004-07-14 Tripep Ab Molecules bloquant l'infectivite virale et methodes d'utilisation associees
EP1450901A4 (fr) * 2001-12-10 2005-05-25 Bristol Myers Squibb Co Composes de (1-phenyl-2-heteroaryl)ethyl-guanidine utiles en tant qu'inhibiteurs de la f1f0 atp hydrolase mitochondriale
CN100525763C (zh) 2002-03-05 2009-08-12 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
WO2003075853A2 (fr) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Derives cycliques servant de modulateurs de l'activite du recepteur de la chimiokine
BR0309485A (pt) * 2002-04-22 2007-03-06 Univ Maryland métodos para avaliar a atividade antiviral de um composto de teste, para reduzir a mortalidade associada à aids, para tratar um humano sofrendo de aids, para avaliar um composto, para selecionar um composto candidato, para identificar um composto, e para inibir a montagem de capsìdeo e a desmontagem de capsìdeo, e, composto ou seu sal farmaceuticamente aceitável
US20050096319A1 (en) * 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
NZ541883A (en) * 2003-02-21 2008-12-24 Tripep Ab Glycinamide derivative for inhibiting HIV replication
GB0329572D0 (en) * 2003-12-20 2004-01-28 Astrazeneca Ab Amide derivatives
EP1725548B1 (fr) 2004-03-12 2015-01-14 Vertex Pharmaceuticals Incorporated Procédés et produits intermédiaires pour la fabrication d'acétals de l'acide aspartique, inhibiteurs de la caspase
NZ588448A (en) * 2004-05-15 2012-01-12 Vertex Pharma Treating seizures using interleukin-1beta converting enzyme (ICE) inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7879891B2 (en) 2005-07-28 2011-02-01 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
WO2011041198A1 (fr) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Dérivés d'imidazole substitués pour traiter la maladie d'alzheimer
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
CN104650016A (zh) * 2015-01-29 2015-05-27 武汉大学 拟三肽类化合物及其制备方法
CN112979636A (zh) * 2021-02-06 2021-06-18 绍兴文理学院 一种含苯硫醚结构的噻唑类化合物及其制备方法和应用
US20240190809A1 (en) * 2021-05-11 2024-06-13 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276298A (en) * 1978-03-24 1981-06-30 Merck & Co., Inc. 2-Aryl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4369183A (en) * 1979-09-06 1983-01-18 Merck & Co., Inc. 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4584397A (en) * 1983-05-09 1986-04-22 G. D. Searle & Co. Protease inhibitors
US4499295A (en) * 1983-05-09 1985-02-12 G. D. Searle & Co. Protease inhibitors
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5158936A (en) * 1986-12-22 1992-10-27 Syntex (U.S.A.) Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
NZ223148A (en) * 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
WO1989004838A1 (fr) * 1987-11-25 1989-06-01 Immunex Corporation Recepteurs d'interleukine-1
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5008245A (en) * 1988-10-27 1991-04-16 University Of Kentucky Research Foundation Novel peptidyl carbamate inhibitors of the enzyme elastase
WO1990013549A1 (fr) * 1989-05-04 1990-11-15 Sterling Winthrop Inc. Derives de saccharine utiles en tant qu'inhibiteurs d'enzymes proteolytiques et leur preparation
US5527882A (en) * 1989-07-07 1996-06-18 The Regents Of The University Of California Polypeptide having an amino acid replaced with N-benzylglycine
CA2021660A1 (fr) * 1989-07-26 1991-01-27 Philippe Bey Inhibiteurs de la peptidose
NZ235155A (en) * 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
AU7775991A (en) * 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
US5416013A (en) * 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
IL99527A (en) * 1990-09-28 1997-08-14 Lilly Co Eli Tripeptide antithrombotic agents
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
DE69226820T2 (de) * 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
JP3190431B2 (ja) * 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
DE69229252T2 (de) * 1991-08-16 1999-12-16 Merck & Co., Inc. DNS, welche das Interleukin-1B-Vorläufer-Converting-Enzym kodiert
US5278061A (en) * 1991-08-16 1994-01-11 Merck & Co., Inc. Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme
US6348570B1 (en) * 1991-08-16 2002-02-19 Merck & Co., Inc. Chromophore containing compounds and their use in determining interleukin-1β convertase activity
EP0533226A3 (en) * 1991-08-16 1993-08-18 Merck & Co. Inc. Novel chromophore containing compounds
DE69133354T2 (de) * 1991-08-30 2004-11-11 Vertex Pharmaceuticals Inc., Cambridge Interleukin 1-beta protease und ihre inhibitoren
GB9123326D0 (en) * 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
AU3479593A (en) * 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
JP3386125B2 (ja) * 1992-02-21 2003-03-17 メルク エンド カンパニー インコーポレーテッド インターロイキン−１β変換酵素阻害剤としてのペプチジル誘導体
WO1993025685A1 (fr) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology Clonage et caracterisation des genes cytocides ced-3 et ced-4
WO1993025694A1 (fr) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology Inhibiteurs de ced-3 et de proteines apparentees
WO1993025683A1 (fr) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology Gene empechant la mort cellulaire programmee
JPH08500242A (ja) * 1992-06-24 1996-01-16 メルク エンド カンパニー インコーポレーテッド インターロイキン１β前駆体の転換酵素をコードするＤＮＡ
WO1994003480A1 (fr) * 1992-07-31 1994-02-17 Pfizer Inc. Derives de l'acide peptidyl 4-amino-2,2-difluoro-3-oxo-1,6-hexane-dioïque utilises comme agents antiinflammatoires
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
CA2109646C (fr) * 1992-11-24 2000-03-07 Gaston O. Daumy Peptides para-nitroanilides
EP0618223A3 (fr) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides inhibent la libération d'interleukine 1-bêta utiles comme agents antiinflammatoires.
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
US5411985A (en) * 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
DK0644197T3 (da) * 1993-06-04 1999-06-07 Vertex Pharma Peptidphosphinyloxymethylketoner som inhibitorer af interleukin-1beta-konverterende enzymer
DK0628550T3 (da) * 1993-06-08 1998-09-28 Vertex Pharma Pyridazin som interleukin-1 beta-omdannede enzyminhibitorer
JPH08511690A (ja) * 1993-06-24 1996-12-10 ザ・ジェネラル・ホスピタル・コーポレーション プログラムされた細胞死遺伝子及びタンパク質
AU7714594A (en) * 1993-08-13 1995-03-14 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1beta converting enzyme
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5508262A (en) * 1993-12-15 1996-04-16 University Of South Florida Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
DE69532113T2 (de) * 1994-03-31 2004-07-29 Vertex Pharmaceuticals Inc., Cambridge Pyrimidin-derivate als interleukin inhibitoren
MX9605196A (es) * 1994-04-29 1997-12-31 Sanofi Winthrop Inc Halometilamidas como inhibidores de la proteasa il-1b.
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
US5498616A (en) * 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme

Also Published As

Publication number Publication date
JP4009320B2 (ja) 2007-11-14
MX9805015A (es) 1998-09-30
WO1997022618A1 (fr) 1997-06-26
DE69635458T2 (de) 2006-06-14
JP2008101008A (ja) 2008-05-01
NZ326555A (en) 2000-03-27
NO982774L (no) 1998-08-19
CZ190598A3 (cs) 1998-11-11
PL188813B1 (pl) 2005-04-29
CN1127511C (zh) 2003-11-12
NO982774D0 (no) 1998-06-16
US5843904A (en) 1998-12-01
RU2213096C2 (ru) 2003-09-27
AU722936C (en) 1997-07-14
CN1500781A (zh) 2004-06-02
HUP9902254A3 (en) 2001-04-28
HK1016611A1 (en) 1999-11-05
PL327333A1 (en) 1998-12-07
JP2004143182A (ja) 2004-05-20
KR20000064454A (ko) 2000-11-06
AU722936B2 (en) 2000-08-17
TR199801168T2 (xx) 1998-09-21
US6162790A (en) 2000-12-19
EP0876395B1 (fr) 2005-11-16
ATE310011T1 (de) 2005-12-15
HUP9902254A2 (hu) 1999-09-28
ZA9610797B (en) 1997-06-26
CA2240489A1 (fr) 1997-06-26
AU1465897A (en) 1997-07-14
CZ292633B6 (cs) 2003-11-12
IL124954A0 (en) 1999-01-26
CN1207743A (zh) 1999-02-10
DE69635458D1 (de) 2005-12-22
EP0876395A1 (fr) 1998-11-11
BR9612191A (pt) 1999-07-13

Similar Documents

Publication Publication Date Title
IL124954A (en) Inhibitors of interleukin-1betaconverting enzyme and pharmaceutical compositions containing the same
MX9606546A (es) Compuestos inhibidores de la enzima conversiva de interleukina-1 beta.
MX9805016A (es) INHIBIDORES DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1 beta.
UA66745C2 (en) INTERLEUKIN-1b-CONVERTING ENZYME INHIBITORS, PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF DISEASES
AU7624798A (en) Inhibitors of interleukin-1 beta converting enzyme
UA96113C2 (en) Inhibitors of caspases
PT966465E (pt) Inibidores do enzima imfdh
AP1498A (en) Inhibitors of impdh enzyme.
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
BG104780A (en) Inhibitors of phospholipase enzymes
AU2901899A (en) 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
AU5896098A (en) Inhibitors of interleukin-1beta converting enzyme
MXPA01003501A (es) Metodo para moderar el estres o tension de las plantas.
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees